Joseph Gathe

Summary

Publications

  1. pmc Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
    Jeffrey P Nadler
    University of South Florida, College of Medicine, Tampa, Florida, USA
    BMC Infect Dis 3:10. 2003
  2. ncbi request reprint HAART at 10: an interview with Joseph Gathe
    Joseph Gathe
    Donald R Watkins Memorial Foundation, Houston, Texas, USA
    Res Initiat Treat Action 11:46-8. 2005
  3. doi request reprint A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks
    Joseph Gathe
    Therapeutic Concepts, Houston, TX, USA
    J Acquir Immune Defic Syndr 50:474-81. 2009
  4. doi request reprint Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients
    Joseph Gathe
    Therapeutic Concepts, Houston, Texas, USA
    Antivir Ther 16:759-69. 2011
  5. doi request reprint Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center
    Joseph Gathe
    Therapeutic Concepts, Houston, TX 77004, USA
    Curr Med Res Opin 24:769-73. 2008
  6. ncbi request reprint Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients
    Joseph C Gathe
    Therapeutic Concepts, 4900 Fannin Street, Houston, TX 77004, USA
    AIDS Res Hum Retroviruses 23:216-23. 2007
  7. ncbi request reprint Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial
    Joseph Gathe
    Therapeutic Concepts, Houston, TX 77004, USA
    Clin Infect Dis 43:1337-46. 2006
  8. ncbi request reprint Adherence and potency with antiretroviral therapy: a combination for success
    Joseph Gathe
    Therapeutic Concepts, Houston, Texas 77004, USA
    J Acquir Immune Defic Syndr 34:S118-22. 2003
  9. ncbi request reprint Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir
    Joseph Gathe
    Baylor College of Medicine, Houston, Texas, USA
    J Acquir Immune Defic Syndr 31:399-403. 2002
  10. ncbi request reprint SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
    Joseph C Gathe
    Therapeutic Concepts, P A, Houston, Texas, USA
    AIDS 18:1529-37. 2004

Detail Information

Publications18

  1. pmc Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
    Jeffrey P Nadler
    University of South Florida, College of Medicine, Tampa, Florida, USA
    BMC Infect Dis 3:10. 2003
    ..Low-dose ritonavir (RTV) boosts plasma amprenavir (APV) exposure. Little has been published on the efficacy, tolerability, and safety of APV 600 mg/RTV 100 mg (APV600/RTV) twice daily (BID) compared to APV 1200 mg BID (APV1200)...
  2. ncbi request reprint HAART at 10: an interview with Joseph Gathe
    Joseph Gathe
    Donald R Watkins Memorial Foundation, Houston, Texas, USA
    Res Initiat Treat Action 11:46-8. 2005
  3. doi request reprint A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks
    Joseph Gathe
    Therapeutic Concepts, Houston, TX, USA
    J Acquir Immune Defic Syndr 50:474-81. 2009
    ..Study M05-730 compared LPV/r tablets dosed once daily vs. twice daily in antiretroviral-naive subjects...
  4. doi request reprint Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients
    Joseph Gathe
    Therapeutic Concepts, Houston, Texas, USA
    Antivir Ther 16:759-69. 2011
    ..This study (VERxVE) compared the efficacy and safety of the new nevirapine extended-release (NVP XR) formulation dosed once daily with NVP immediate release (IR) twice daily in treatment-naive patients...
  5. doi request reprint Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center
    Joseph Gathe
    Therapeutic Concepts, Houston, TX 77004, USA
    Curr Med Res Opin 24:769-73. 2008
    ....
  6. ncbi request reprint Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients
    Joseph C Gathe
    Therapeutic Concepts, 4900 Fannin Street, Houston, TX 77004, USA
    AIDS Res Hum Retroviruses 23:216-23. 2007
    ..The 500 mg/200 mg dose achieved the best efficacy, safety, and pharmacokinetic profile in this highly treatment-experienced population and was selected for the pivotal phase 3 studies...
  7. ncbi request reprint Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial
    Joseph Gathe
    Therapeutic Concepts, Houston, TX 77004, USA
    Clin Infect Dis 43:1337-46. 2006
    ....
  8. ncbi request reprint Adherence and potency with antiretroviral therapy: a combination for success
    Joseph Gathe
    Therapeutic Concepts, Houston, Texas 77004, USA
    J Acquir Immune Defic Syndr 34:S118-22. 2003
  9. ncbi request reprint Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir
    Joseph Gathe
    Baylor College of Medicine, Houston, Texas, USA
    J Acquir Immune Defic Syndr 31:399-403. 2002
    ....
  10. ncbi request reprint SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
    Joseph C Gathe
    Therapeutic Concepts, P A, Houston, Texas, USA
    AIDS 18:1529-37. 2004
    ..To compare the magnitude and durability of the antiviral response to fosamprenavir (FPV) plus ritonavir (RTV) once-daily (FPV/r QD) with nelfinavir twice-daily (NFV BID), each administered with abacavir and lamivudine twice-daily...
  11. ncbi request reprint Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study
    Joseph C Gathe
    Therapeutic Concepts, P A, Houston, Texas, USA
    Clin Ther 28:745-54. 2006
    ....
  12. doi request reprint Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults
    Rosa F Yeh
    University of Houston, College of Pharmacy, Houston, TX, USA
    J Int Assoc Physicians AIDS Care (Chic) 9:273-7. 2010
    ..3% vs3.3%; P = .004). Quality-of-life measures, tolerability, and diarrhea improved with the LPV/r tablet formulation compared to SGC in HIV-positive patients not receiving other antiretroviral therapy (ART)...
  13. pmc Cord blood stem cell therapy for acquired immune deficiency syndrome
    Gabriel Gonzalez
    Department of Genetics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Stem Cells Dev 18:1-2. 2009
    ..Here we suggest that public cord blood repositories are likely to contain CCR5 homozygous units that could be used as a therapy for HIV-infected individuals...
  14. ncbi request reprint A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen
    Margaret A Johnson
    Royal Free Center for HIV Medicine, London, United Kingdom
    J Acquir Immune Defic Syndr 43:153-60. 2006
    ..To evaluate the safety and noninferiority and to explore the efficacy of administration of once-daily versus twice-daily lopinavir/ritonavir (LPV/r) in antiretroviral-naive HIV-1-infected subjects...
  15. ncbi request reprint Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens
    I Chan Huang
    University of Florida, Gainesville, USA
    Antivir Ther 13:15-25. 2008
    ..This study assesses the influence of adverse events (AEs) on health-related quality of life (HRQOL) and change in HRQOL in patients treated with TPV/r versus CPI/r regimens...
  16. ncbi request reprint Antiretroviral rounds. Resistance: what you don't know--can it hurt you?
    Joseph C Gathe
    AIDS Clin Care 20:51-2. 2008
  17. ncbi request reprint Impact of resistance to antiretroviral therapy in the minority community
    Allen E Rodriguez
    University of Miami School of Medicine, Miami, Florida, USA
    AIDS Read 14:S9-11. 2004
    ....
  18. ncbi request reprint Beyond efficacy: the impact of combination antiretroviral therapy on quality of life
    Paul E Sax
    Brigham and Women s Hospital, Division of Infectious Diseases, 75 Francis Street, PBB A 4, Boston, Massachusetts 02115, USA
    AIDS Patient Care STDS 19:563-76. 2005
    ..As long as the virologic activity of these newer PIs is comparable to that of existing options, differentiating features beyond efficacy are important in the choice of an appropriate treatment regimen for patients with HIV...